In response to antigens from the COVID virus and/or COVID vaccine, our body creates antibodies to these antibodies, which resemble the shape & binding affinity of the ACE2 receptor. To clear out these antibodies, our body creates antibodies to these antibodies, termed: “anti-idiotype antibodies”. These anti-idiotype antibodies may resemble the shape and binding affinity of the original anti-gen. For example, these anti-idiotype antibodies may resemble the original antigenic spike protein. For this reason, these anti-idiotype antibodies may cause similar damage to the original spike protein: for example, by binding to Ace2 receptors, disrupt their normal function, and generate continuous inflammation and the other pathological effects we know the spike protein causes.
The proposed mechanism of action is the following:
- Our body creates antigen-specific antibodies in response to spike protein on virus or vaccine, which have similar shape and binding affinity to the ACE2 receptor
- Macrophages, dendritic cells, and other immune responses digest these antigen-specific antibodies, and express this receptor on their surface
- In response, the antibodies against these antibodies (“anti-idiotype antibodies”) form a shape/binding region similar to the original spike protein
- These anti-idiotype antibodies are antibodies against our original anti-gene specific antibodies, that resemble the spike protein.
- These anti-idiotype antibodies can, like the original spike protein, bind to Ace2 receptors and cause damage
- If the original antigen-specific antibody that the body produced was not for the spike protein, but for another, less toxic protein (eg. an M protein), then the anti-idiotype response would not resemble the spike protein
This account would help explain why vaccines often create temporary relief in LC patients. Under this theory, the body will produce anti-spike protein antibodies after vaccination. These antibodies will bind to and neutralize the anti-idiotype antibodies that have been created in the LC patient (the antibodies that are in the shape of the spike proteins) and mitigate their propagation+damage.
Peer Review #
- tested plasma or serum for ACE2 antibodies in 67 patients with known SARS-CoV-2 infection and 13 with no history of infection
- None of the 13 patients without history of SARS-CoV-2 infection and 1 of the 20 outpatients that had a positive PCR test for SARS-CoV-2 had levels of ACE2 antibodies above the cutoff threshold
- 26/32 (81%) in the convalescent group and 14/15 (93%) of patients acutely hospitalized had detectable ACE2 antibodies
- Anti-Ace2 antibodies are developed in acute and recovering Covid patients
- The paratopes, or antigen-binding domains, of some of the resulting anti-idiotype (or “Ab2”) antibodies that are specific for Ab1 can structurally resemble that of the original antigens themselves.
- Thus, the Ab2 antigen-binding region can potentially represent an exact mirror image of the initial targeted antigen in the Ab1 response, and Ab2 antibodies have even been examined for potential use as a surrogate for the antigen in vaccine studies.
- However, as a result of this mimicry, Ab2 antibodies also have the potential to bind the same receptor that the original antigen was targeting (Figure 1). Ab2 antibodies binding to the original receptor on normal cells therefore have the potential to mediate profound effects on the cell that could result in pathologic changes, particularly in the long term — long after the original antigen itself has disappeared.